Quick Takeaways
- GSK plc has 7 issuer positions tracked on this page.
- Estimated disclosed ownership value: $446,013,072.
- Recent insider filing activity is available below.
Insider Trading & Ownership of GSK plc
- Location
- London
- Summary
- The estimated value of insider holdings of GSK plc is at least $446,013,072 dollars as of 15 Dec 2025. GSK plc is the 10%+ Owner of Wave Life Sciences Ltd. and owns shares of Wave Life Sciences Ltd. (WVE) stock worth about $346.67M. GSK plc is the 10%+ Owner of Lyell Immunopharma, Inc. and owns shares of Lyell Immunopharma, Inc. (LYEL) stock worth about $68.98M. GSK plc is the 10%+ Owner of CVRx, Inc. and owns shares of CVRx, Inc. (CVRX) stock worth about $18.7M. GSK plc is the 10%+ Owner of Spero Therapeutics, Inc. and owns shares of Spero Therapeutics, Inc. (SPRO) stock worth about $11.67M.
- Signature
- /s/ Victoria Whyte, Authorized Signatory, GSK plc
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow GSK plc and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Wave Life Sciences Ltd. ($346,668,129).
- Past-year value change for that position: +$27,930,000.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of GSK plc
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| WVE | Wave Life Sciences Ltd. | 10%+ Owner | $346,668,129 | +$27,930,000 | +8.8% | 11 Dec 2025 |
| LYEL | Lyell Immunopharma, Inc. | 10%+ Owner | $68,977,271 | 21 Jun 2021 | ||
| CVRX | CVRx, Inc. | 10%+ Owner | $18,695,602 | 02 Jul 2021 | ||
| SPRO | Spero Therapeutics, Inc. | 10%+ Owner | $11,672,070 | 07 Nov 2022 | ||
| ME | 23andMe Holding Co. | 10%+ Owner | 16 Jun 2021 | |||
| INVA | Innoviva, Inc. | 10%+ Owner | 20 May 2021 | |||
| TBPH | Theravance Biopharma, Inc. | Former 10% Owner | 16 Sep 2022 |
Insider Transactions Reported by GSK plc:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.